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ABSTRACT
Introduction This study aimed to examine the association 
between anemia and the incidence of dementia in patients 
with new- onset type 2 diabetes.
Research design and methods This study used the 
Korean National Health Insurance Service- Health Screening 
Cohort and included 32 590 participants aged ≥40 years 
who were diagnosed with new- onset type 2 diabetes 
between 2004 and 2007 and followed up until 2013. 
Anemia was defined according to the criteria provided by 
the WHO, hemoglobin <120 g/L for women and <130 g/L 
for men, and was measured from after diagnosis date of 
type 2 diabetes to 2007. Dementia was defined by the 
Classification of Diseases 10th revision code as primary 
diagnosis and was measured from after hemoglobin 
measurement to 2013. We calculated the adjusted HR 
(AHR) and 95% CI to assess the risk of dementia using 
multivariable Cox proportional hazards regression models.
Results We identified 1682 patients who developed 
dementia within a 7.5- year follow- up. Among patients with 
type 2 diabetes, patients with anemia were associated 
with an increased risk of dementia than those without 
anemia (AHR, 1.21; 95% CI 1.06 to 1.39). Patients with 
mild (AHR, 1.18; 95% CI 1.03 to 1.38) and moderate (AHR, 
1.39; 95% CI 1.06 to 1.83) anemia were associated with 
an increased risk of dementia than those without anemia 
among patients with type 2 diabetes. Men (AHR, 1.47; 
95% CI 1.16 to 1.83) and middle- aged adults (AHR, 1.31; 
95% CI 1.03 to 1.75) with anemia were associated with an 
increased risk of dementia than their counterparts without 
anemia among patients with type 2 diabetes.
Conclusions Our findings suggest that anemia is 
significantly associated with an increased risk of dementia 
among patients with newly diagnosed type 2 diabetes.
INTRODUCTION
Type 2 diabetes and dementia are main 
chronic conditions with increasing prevalence 
in Korea and worldwide and are anticipated to 
have considerable effects on the aging popu-
lation.1–4 Previous evidence suggests that type 
2 diabetes is related to a decline in cognitive 
function and the incidence of dementia.5–11 
It has been hypothesized that insulin resis-
tance and hyperglycemia affect cerebrovas-
cular pathologies; however, the underlying 
mechanisms remain unclear.12 13 Further-
more, the number of people with dementia 
is increasing rapidly and is estimated to reach 
82 million in 2030 and 152 million in 2050.14 
Although dementia has important economic 
and social implications and the total global 
social cost for managing dementia was esti-
mated to be US$818 billion in 2015,15 there is 
no specific treatment for dementia in patients 
with type 2 diabetes. It is, therefore, signifi-
cant to explore the risk factors for incident 
dementia among patients with type 2 diabetes.
Anemia has been defined as having hemo-
globin concentration lower than 130 g/L and 
120 g/L in men and women, respectively.16 
Significance of this study
What is already known about this subject?
 ► Type 2 diabetes is associated with an increased in-
cidence of dementia.
 ► Anemia frequently occurs in patients with type 2 di-
abetes and is associated with a decline in cognitive 
function and increased risk of developing dementia.
What are the new findings?
 ► Among patients with newly diagnosed type 2 dia-
betes, patients with anemia were associated with 
an increased risk of dementia than those without 
anemia.
 ► Among patients with type 2 diabetes, patients with 
mild or moderate anemia were independently as-
sociated with a higher incidence of dementia than 
those without anemia.
 ► Among patients with type 2 diabetes, men and 
middle- aged adults with anemia were associated 
with an increased risk of developing dementia than 
their counterparts without anemia.
How might these results change the focus of 
research or clinical practice?
 ► Anemia is a modifiable factor, and careful survey and 
optimal management of this disease in patients with 
type 2 diabetes may be a helpful and applicable way 
to prevent dementia partially.
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There is an increasing interest regarding the role of 
anemia in the development of dementia in the general 
population.16–25 A chronic brain hypo- oxygenation due 
to anemia could be the biological mechanism under-
lying this association.17 A significant reduction in brain 
oxygenation results in reversible cognitive impairment26; 
conversely, an increase in the circulating blood oxygen 
levels improves cognitive performance. A double- blind, 
placebo- controlled study implied improvement in cogni-
tive performance following oxygen administration.27
Previous studies evaluating the association between 
anemia and dementia have been performed in 
general16 21 22 25 or specific population, such as patients with 
chronic kidney disease (CKD)23 or in older adults,17–20 24 
but data on the relationship between anemia and the risk 
of incident dementia in patients with type 2 diabetes are 
limited. Anemia frequently occurs in patients with type 
2 diabetes,28 and previous study reported that the risk of 
anemia in patients with diabetes is approximately two to 
three times higher than that of a general population.29 
The underlying mechanisms may be due to features of 
the diabetic milieu (systemic inflammation, functional 
hematinic deficiencies, resistance of bone marrow to 
erythropoietin, and red cell abnormalities) that cause 
hemoglobin levels to drop.30 Considering that patients 
with diabetes may be more vulnerable to anemia and that 
anemia was a major risk factor for dementia, the evidence 
for association between anemia and dementia among 
patients with type 2 diabetes needed to be investigated.
This study, therefore, aimed to examine the associ-
ation between anemia and the incidence of dementia 
in patients with newly diagnosed type 2 diabetes using 
nationwide population- based cohort data. We also aimed 
to identify the risk of dementia development according 
to the severity of anemia and explore the relationship 
between anemia and incidence of dementia stratified by 
sex and age groups.
MATERIALS AND METHODS
Data and study sample
We used data from the Korean National Health Insur-
ance Service- Health Screening Cohort (NHIS- HEALS) 
database.31 The NHIS is the sole insurance provider in 
Korea and covers almost all citizens. All enrollees of the 
insurance system aged ≥40 years are entitled to standard 
medical examinations biennially that include a ques-
tionnaire survey on lifestyle and medical history, height, 
weight, and blood pressure (BP) measurements, and 
laboratory tests. The NHIS- HEALS data were obtained 
from the 2002–2003 health screening participants who 
were aged between 40 and 79 years in 2002 and were 
followed up until 2013. The NHIS- HEALS consisted of 
514 866 health screening participants, who accounted for 
approximately 10% of all health screening participants 
in 2002 and 2003 by simple random sampling. This data-
base includes patients’ demographic characteristics and 
clinical information concerning treatments, diagnoses, 
and prescribed drugs of all visits (outpatient, inpatients, 
and pharmacy visits) provided by healthcare facilities. 
Moreover, it is connected to the Korean death registra-
tion database, which includes dates and causes of deaths.
Of the 513 268 patients who were included in the 2004–
2007 NHIS- HEALS database, we excluded those with type 
1 diabetes from 2002 to 2007 (n=6629). Moreover, we 
excluded patients without type 2 diabetes to enroll those 
who were diagnosed with type 2 diabetes from 2004 to 
2007 as study participants (n=425 161). Type 2 diabetes 
(n=81 478) was defined as the existence of at least one of 
the following criteria: (1) fasting blood glucose level of 
≥126 mg/dL (7 mmol/L), (2) at least one additional diag-
nosis of type 2 diabetes within 6 months from the initial 
date of diagnosis under the ICD-10 codes E11–E14, and 
(3) use of oral hypoglycemic agents or insulin. In subjects 
who were diagnosed with type 2 diabetes between 2004 
and 2007 (baseline period), we excluded those who were 
diagnosed with type 2 diabetes before the baseline period 
to recruit only those with newly diagnosed type 2 diabetes 
(n=40 914). Additionally, we excluded study patients who 
had a history of dementia before hemoglobin measure-
ment to minimize reverse causality (n=176) and indi-
viduals who had no health screening data after diabetes 
diagnosis (n=7792) or missing data regarding hemo-
globin (n=6). The final study sample included 32 590 
patients with new- onset type 2 diabetes (online supple-
mentary figure 1).
Measurement
The outcome variable in this study is dementia. Dementia 
was measured by ICD-10 codes (F00, F01, F02, F03, G30, 
or G31) as primary diagnosis32 and was measured from 
after hemoglobin measurement between 2004 and 2007 
until December 31, 2013. This definition of dementia 
incidence was applied to outpatients and inpatients.
We used anemia as the independent variable, which 
was defined according to the WHO criteria, hemo-
globin <120 g/L for women and <130 g/L for men,33 and 
anemia was measured from after diagnosis date of type 2 
diabetes to 2007. The severity of anemia was categorized 
as mild (hemoglobin ≥110 g/L), moderate (hemoglobin 
80–109 g/L), or severe (hemoglobin <80 g/L) according 
to the WHO criteria. Serum hemoglobin concentration 
was estimated using the cyanmethemoglobin method.
Potential confounding factors were age, sex, body mass 
index (BMI), systolic and diastolic BP, fasting glucose, 
total cholesterol, smoking, heavy drinking, exercise, 
household income, residential area, and comorbidities. 
The potential confounding factors except for comorbid-
ities were measured on the date of hemoglobin measure-
ment, while comorbidities were measured by screening 
information for all medical records from January 1, 
2002 to the date of hemoglobin measurement. Age was 
measured as time scale in the Cox proportional hazards 
models. BP was estimated with the individuals seated 
following at least 5 min of rest. Total cholesterol and 
fasting glucose were estimated by blood samples following 
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overnight fasting. The participants were divided into the 
following age groups: middle- aged (40–64 years) and 
older adults (≥65 years). The WHO recommendations 
for Asian populations were used to categorize individ-
uals into five BMI groups: <18.5 kg/m2 (underweight), 
18.5–22.9 kg/m2 (normal), 23.0–24.9 kg/m2 (over-
weight), 25.0–29.9 kg/m2 (class I obese), or ≥30 kg/m2 
(class II obese).34 Regarding smoking status, participants 
were classified as current smokers, ex- smokers, or non- 
smokers. Individuals who consumed ≥30 g/day of alcohol 
were classified as heavy drinkers.35 Exercise was defined 
as performing exercise at least once a week. Household 
income was classified as follows: (1) low income (<40th 
percentile), (2) middle income (41st–80th percentile), 





n % n %
Total 32 590 3104 9.5 29 486 90.5
Women 12 040 1731 55.8 10 309 35.0 <0.001
Age (years) <0.001
  40–64 24 635 1771 57.1 22 864 77.5
  ≥65 7955 1333 42.9 6622 22.5
BMI (kg/m2) <0.001
  ≤18.5 609 177 5.7 432 1.5
  18.5–23 8985 1278 41.2 7707 26.1
  23–25 8645 719 23.2 7926 26.9
  25–30 12 769 840 27.1 11 929 40.5
  ≥30 1582 90 2.9 1492 5.1
BP (mm Hg)
  Systolic 130.8±17.1 127.7 17.8 131.1 17.0 <0.001
  Diastolic 81.0±11.0 77.6 11.1 81.4 10.9 <0.001
Fasting glucose (mg/dL) 132.6±46.3 129.4 49.2 132.9 46.0 <0.001
Total cholesterol (mg/dL) 202.5±40.7 190.2 41.5 203.8 40.4 <0.001
Current smokers 7297 469 15.1 6828 23.2 <0.001
Heavy drinkers 2007 128 4.1 1879 6.4 <0.001
Exercisers 15 177 1208 38.9 13 969 47.4 <0.001
Household income <0.001
  Low 10 155 1184 38.1 8971 30.4
  Middle 12 461 1070 34.5 11 391 38.6
  High 9974 850 27.4 9124 30.9
Residential area <0.001
  Metropolitan 4825 383 12.3 4442 15.1
  Urban 8962 843 27.2 8119 27.5
  Rural 18 803 1878 60.5 16 925 57.4
Comorbidities
  Hypertension 15 048 1527 49.2 13 521 45.9 <0.001
  Dyslipidemia 11 666 1141 36.8 10 525 35.7 0.240
  CKD 245 56 1.8 189 0.6 <0.001
  Ischemic heart disease 5339 625 20.1 4714 16.0 <0.001
  Stroke 1725 240 7.7 1485 5.0 <0.001
  Depressive disorders 2990 395 12.7 2595 8.8 <0.001
  Cancer 2522 397 12.8 2125 7.2 <0.001
Values are presented as mean±SD or n (%).
BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease.
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or (3) high income (81st–100th percentile). Residen-
tial area was classified as metropolitan (capital), urban 
(local government with >1 million residents), or rural 
(otherwise). Comorbidities included hypertension (ICD-
10: I10–I15), dyslipidemia (ICD-10: E78), CKD (ICD-10: 
N18), stroke (ICD-10: I60–I63), ischemic heart disease 
(ICD-10: I20–I25), depressive disorders (ICD-10: F32–
F33), and cancer (ICD-10: C00–C99).
Statistical analysis
Patients’ demographic and clinical characteristics were 
compared according to the presence of anemia using 
an independent t- test for continuous variables and Pear-
son’s χ2 test for categorical variables, respectively. Data 
are expressed as mean±SD for continuous variables or as 
numbers with percentages for categorical variables. We 
measured age- standardized incidence rates (95% CI) of 
dementia per 1000 person- years according to presence 
or severity of anemia. For each study participant, risk of 
dementia was estimated from the date of hemoglobin 
measurement after diabetes diagnosis between 2004 and 
2007 until December 31, 2013. The length of follow- up 
was measured in days, and all study participants were 
followed up until the onset of dementia, withdrawal from 
the insurance system, death from any causes, or the end 
of 2013, whichever occurred first.
We calculated the adjusted HR (AHR) and 95% CI 
to determine the association between anemia and the 
incidence of dementia using Cox proportional hazards 
regression models. First, we analyzed the effect of anemia 
on the incidence of dementia in patients with new- onset 
type 2 diabetes. Second, we also identified the risk of 
dementia according to the severity of anemia. Finally, we 
explored the relationship between anemia and the inci-
dence of dementia stratified by sex and age groups.
All data extraction and statistical analyses were 
performed using SAS V.9.4 software. Proportional 
hazards assumptions were evaluated statistically and satis-
fied for all models.
RESULTS
Our study enrolled 32 590 patients with new- onset type 
2 diabetes aged ≥40 years and observed 1682 events 
of dementia during an average of 7.5±1.7 years of 
follow- up. Table 1 shows the general characteristics 
of the study participants according to the severity of 
anemia. The proportions of women (55.8% vs 35.0%), 
older adults (42.9% vs 22.5%), underweight partici-
pants (5.7% vs 1.5%), participants with low household 
income (38.1% vs 30.4%), participants living in rural 
areas (60.5% vs 57.4%), and participants with comor-
bidities (hypertension (49.2% vs 45.9%), CKD (1.8% 
vs 0.6%), ischemic heart disease (20.1% vs 16.0%), 
stroke (7.7% vs 5.0%), depressive disorders (12.7% vs 
8.8%), and cancer (12.8% vs 7.2%)) with anemia were 
significantly higher than those without anemia among 
patients with type 2 diabetes. The average systolic 
(127.7 mm Hg vs 131.1 mm Hg) and diastolic (77.6 mm 
Hg vs 81.4 mm Hg) BP, fasting glucose (129.4 mg/dL 
vs 132.9 mg/dL), and total cholesterol (190.2 mg/dL vs 
203.8 mg/dL) and the proportions of current smokers 
(15.1% vs 23.2%), heavy drinkers (4.1% vs 6.4%), and 
exercisers (38.9% vs 47.4%) with anemia were signifi-
cantly lower than those without anemia among patients 
with type 2 diabetes.
Table 2 presents the AHR and 95% CI for the inci-
dence of dementia according to the presence and 
severity of anemia among patients with newly diagnosed 
type 2 diabetes. After adjusting for sex and age, model 
1 showed that patients with anemia were at a higher 
risk of dementia (AHR, 1.35; 95% CI 1.18 to 1.53) 
than those without anemia among patients with type 2 
Table 2 Association between anemia and incidence of dementia in patients with new- onset type 2 diabetes










Model 1† Model 2‡ Model 3§
Model 1 Anemia
No 29 486 1396 221 429 43 (41 to 45) 1.00
Yes 3104 286 21 828 73 (66 to 79) 1.35 (1.18 to 1.53)*** 1.33 (1.12 to 1.51)*** 1.21 (1.06 to 1.39)*
Model 2 Severity of anemia
None 29 486 1396 221 429 43 (41 to 45) 1.00
Mild 2484 224 17 618 71 (64 to 78) 1.32 (1.13 to 1.51)*** 1.30 (1.11 to 1.49)** 1.18 (1.03 to 1.38)*
Moderate 584 61 3972 81 (65 to 98) 1.58 (1.21 to 2.05)*** 1.55 (1.24 to 2.01)*** 1.39 (1.06 to 1.83)*
Severe 36 1 238 43 (1 to 87) 0.69 (0.11 to 5.07) 0.63 (0.11 to 4.74) 0.68 (0.10 to 4.87)
*P<0.05, **P<0.01, ***P<0.001.
†HRs were estimated after adjusting for sex and age.
‡HRs were estimated after adjusting for sex, age, household income, and residential area.
§HRs were estimated after adjusting for sex, age, body mass index, blood pressure, fasting glucose, total cholesterol, smoking, heavy alcohol drinking, exercise, 
household income, residential area, and comorbidities.
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diabetes. Among patients with type 2 diabetes, the risk of 
dementia was significantly higher in patients with mild 
(AHR, 1.32; 95% CI 1.13 to 1.51) and moderate (AHR, 
1.58; 95% CI 1.21 to 2.05) anemia than those without 
anemia. After adjusting for sex, age, residential area, and 
household income, model 2 revealed that patients with 
anemia were at a higher risk of dementia (AHR, 1.33; 
95% CI 1.12 to 1.51) than those without anemia among 
patients with type 2 diabetes. Among patients with type 
2 diabetes, the risk of dementia was significantly higher 
in patients with mild (AHR, 1.30; 95% CI 1.11 to 1.49) 
and moderate (AHR, 1.55; 95% CI 1.24 to 2.01) anemia 
than those without anemia. After adjusting for all poten-
tial confounding factors, model 3 indicated that patients 
with anemia were at a higher risk of dementia (AHR, 1.21; 
95% CI 1.06 to 1.39) than those without anemia among 
patients with type 2 diabetes. Among patients with type 2 
diabetes, the risk of dementia was significantly higher in 
patients with mild (AHR, 1.18; 95% CI 1.03 to 1.38) and 
moderate (AHR, 1.39; 95% CI 1.06 to 1.83) anemia than 
those without anemia. However, there was no significant 
association between severe anemia and risk of developing 
dementia in all models.
Figure 1 shows the results of the analysis of the asso-
ciation between anemia and the incidence of dementia 
according to sex and age. Among men with type 2 
diabetes, patients with anemia were at a higher risk of 
dementia (AHR, 1.47; 95% CI 1.16 to 1.83) than those 
without anemia. In middle- aged adults with type 2 
diabetes, the risk of dementia increased significantly in 
patients with anemia than those without (AHR, 1.31; 
95% CI 1.03 to 1.75). In women and older adults, there 
was no statistically significant association between anemia 
and the incidence of dementia.
DISCUSSION
This study had three main findings. First, among patients 
with newly diagnosed type 2 diabetes, patients with anemia 
were associated with an increased risk of dementia than 
those without anemia. Second, among patients with type 
2 diabetes, patients with mild or moderate anemia were 
associated with an increased risk of dementia develop-
ment than those without anemia. Third, among patients 
with type 2 diabetes, men and middle- aged adults with 
anemia were associated with an increased risk of dementia 
than their counterparts without anemia.
Our findings were in line with previous studies which 
had investigated the association between anemia and 
dementia,16–22 24 25 except for a research on patients with 
CKD.23 Although the mechanisms linking anemia to the 
incidence of dementia have not been fully established, 
a few hypotheses have been suggested. First, chronic 
brain hypoxia associated with anemia may affect patients’ 
cognitive function by expediting the accumulation of 
amyloid-β.36 Second, anemia has been related to the 
progression of white matter disease.37 A meta- analysis 
study showed a significant relationship between white 
matter hyperintensities and the incidence of dementia. 
Finally, anemia associated with deficiency in micronu-
trients such as vitamin B12 and iron may be related to 
dementia.20 Iron deficiency (a mineral that plays a critical 
role in storage and transport of oxygen in the brain) may 
cause cognitive decline or cerebral hypoxia.38 Deficiency 
in vitamin B12 has also been associated with dementia.
39
Our findings showed that patients with mild or 
moderate anemia had higher incidence of dementia 
than those without anemia. Furthermore, the age- 
standardized incidence rate of dementia of moderate 
anemia (0.081) was higher than that of mild anemia 
(0.071). Previous research verified that patients with 
lower hemoglobin concentration had a higher AHR 
value of incident dementia.17 Another study showed that 
severe anemia was independently related to the inci-
dence of dementia.24 These findings support the notion 
that the risk of developing dementia increases when the 
hemoglobin concentration decreases. One potential 
mechanism that can possibly explain the dose–response 
association is that mild anemia may have lesser effect on 
oxygen delivery to the brain through a compensatory 
reaction, such as vascular dilation, to maintain the cere-
bral blood flow than moderate or severe anemia.40
Although the prevalence of anemia and dementia 
is more frequent in women than in men,24 our find-
ings showed that anemia was independently associ-
ated with the incidence of dementia in men with type 
2 diabetes, which is different from results in previous 
studies conducted in the general population. Denny et 
al18 suggested that the effect of anemia on dementia is 
greater in women than in men. Chung et al21 found that 
female, and not male, patients with dementia had higher 
prevalence of iron deficiency anemia. Our results also 
showed a significant association between anemia and 
the incidence of dementia in middle- aged adults with 
type 2 diabetes. Anemia and dementia commonly occur 
in older adults,41 42 and previous studies showed signifi-
cant relationship between anemia and dementia among 
older adults.17–20 24 In patients with type 2 diabetes, our 
Figure 1 Association between anemia and incidence of 
dementia according to sex and age.
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findings suggest that men and middle- aged adults with 
anemia were significantly associated with risk of dementia 
compared with their counterparts without anemia, 
respectively.
Our study had several limitations that need to be 
considered. First, we could not determine the severity of 
dementia from the medical records. Second, although 
we examined the incidence of dementia according to the 
severity of anemia, only one case of severe anemia was 
associated with incidence of dementia. Future research 
is warranted to explore the association between severe 
anemia and dementia using larger data. Third, although 
we excluded patients with a dementia diagnosis made 
before the date of anemia measurement, there may have 
been reverse causality. Fourth, we were not able to obtain 
patients’ genetic information, such as APOE4 carrier 
status, and we were not able to assess their education and 
literacy levels, which might have an effect on cognitive 
function.43 Finally, as the Korean population is predom-
inantly of Asian descent, further studies are needed to 
confirm that these findings are consistent with other 
ethnicities and geographical regions.
Despite these limitations, the strengths of our study 
included its longitudinal design and the abundant avail-
able data regarding demographics, lifestyle variables, 
comorbidities, and biomedical information. To the 
best of our knowledge, this is the first study to examine 
the association between anemia and the incidence of 
dementia among patients with new- onset type 2 diabetes.
In conclusion, this cohort study of the Korean popu-
lation demonstrated that anemia is significantly associ-
ated with an increased risk of dementia among patients 
with newly diagnosed type 2 diabetes. Anemia is a modi-
fiable factor, and most of its types occur due to insuffi-
cient nutrition (vitamins or iron).44 Moreover, anemia 
of chronic disease may be modified through treatment 
(eg, erythropoietin therapy in diabetes).45 Therefore, we 
suggest that careful examination and optimal manage-
ment of anemia in patients with type 2 diabetes may be 
helpful and applicable methods to partially prevent the 
development of dementia.
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